Brief: Alpha Tau Announces New Research Collaboration To Study The Potential Of Alpha Dart To Enhance Immune Stimulation
20/01/2022 11:54
Jan 20 (Reuters) - Healthcare Capital Corp HCCC.O :
* ALPHA TAU ANNOUNCES NEW RESEARCH COLLABORATION TO STUDY THE POTENTIAL OF
ALPHA
DART TO ENHANCE IMMUNE STIMULATION IN THE TREATMENT OF BREAST CANCER
* ALPHA TAU ANNOUNCES NEW RESEARCH COLLABORATION TO STUDY POTENTIAL OF ALPHA
DART
TO ENHANCE IMMUNE STIMULATION IN TREATMENT OF BREAST CANCER
Source text for Eikon: ID:nPn8gj7Q4a
Further company coverage: HCCC.O
Recent news on Alpha Tau Medical
See all newsBrief: Alpha Tau Completes Patient Enrollment In Its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal Of FDA Approval Of Alpha Dart® To Treat Recurrent Cutaneous Squamous Cell Carcinoma
Brief: Alpha Tau Announces 100% Local Disease Control Rate And Favorable Safety Profile Observed In Alpha Dart® Pancreatic Cancer Trials Presented At Ddw 2026
Brief: Alpha Tau Medical Files To Offer Up To $300 Million In Securities - SEC Filing
Brief: Alpha Tau Announces First-Ever Oral Presentation Of Alpha Dart® Pancreatic Cancer Data At Digestive Disease Week (Ddw) 2026
Brief: Alpha Tau Medical Receives Japanese Marketing Approval For Alpha Dart In Head And Neck Cancer